Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06721013 · ClinicalTrials.gov registry record · Phase 1
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
A Phase 1 study of Immune Thrombocytopenia (ITP), sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
- 20
- Study locations
NCT06721013: Recruiting Phase 1 study of Immune Thrombocytopenia (ITP), sponsored by Eli Lilly and Company.
NCT06721013 is a Phase 1 study of Immune Thrombocytopenia (ITP) that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 58 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06721013, a Phase 1 study of Immune Thrombocytopenia (ITP), is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the phase 1 part of this study is to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and safety of multiple pirtobrutinib dosages versus placebo. The study drug will be administered orally in participants with Primary Immune Thrombocytopenia (ITP). Blood tests will be performed to check how much pirtobrutinib gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 16 weeks for phase 1 dose-escalation and 28 weeks for phase 2 dose-optimization, excluding screening.
Primary Outcome
A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pirtobrutinib
Study Locations (20)
Other
- Nanfang Hospital of Southern Medical University - Guangzhou
- Qilu Hospital of Shandong University - Jinan
- Hematology Hospital of the Chinese Academy of Medical Sciences - Tianjin
- Union Hospital Tongji Medical College Huazhong University of Science and Technology - Wuhan
- OUH - Odense C
- Hôpital Henri Mondor - Créteil
- CHU Dijon - Hopital du Bocage - Dijon
- CHU Bordeaux - Hôpital Haut-Lévêque - Pessac
- Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS - Bologna
Texas
- Texas Oncology - Central South - Austin
- MD Anderson Cancer Center - Houston
- Texas Oncology Gulf Coast - The Woodlands
California
- USC Norris Comprehensive Cancer Center - Los Angeles
- Stanford University - Stanford
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
Florida
- University of Miami Hospital and Clinics Sylvester Comprehensive Cancer Center - Miami
Illinois
- Bleeding and Clotting Disorders Institute - Peoria
Louisiana
- Ochsner Clinical Foundation - New Orleans
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2025-07-30 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
What NCT06721013 shows while recruiting
NCT06721013 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 1 condition, with Immune Thrombocytopenia (ITP) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06721013 names 20 study sites across 9 states, led by Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT06721013 about?
NCT06721013 is a clinical study titled "A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia". The purpose of the phase 1 part of this study is to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and safety of multiple pirtobrutinib dosages versus placebo. The study drug will be administered orally i...
What is the current status of trial NCT06721013?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2025-07-30. Estimated completion is 2027-02.
What conditions does trial NCT06721013 study?
This clinical trial studies the following conditions: Immune Thrombocytopenia (ITP).
What interventions are being tested in trial NCT06721013?
The interventions under investigation include: Placebo (DRUG), Pirtobrutinib (DRUG).
Who is sponsoring clinical trial NCT06721013?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06721013 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune Thrombocytopenia (ITP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06721013's enrollment target sits among peer trials
58 896th of 2000 higher than 1,100 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI